PETVIVO HOLDINGS, INC. TO EXHIBIT AT THE WESTERN VETERINARY CONFERENCE IN LAS VEGAS, NEVADA
February 13 2023 - 8:00AM
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo") an
emerging biomedical device company focused on the commercialization
of innovative medical therapeutics for pets announced today it will
be exhibiting at the Western Veterinary Conference to be held
February 19th to February 22nd, 2023 at the Mandalay Bay Convention
Center in Las Vegas, Nevada.
PetVivo intends to exhibit its lead product,
SPRYNG™ with OsteoCushion™ Technology, an intra-articular
injectable veterinary medical device consisting of sterilized,
extra-cellular matrix microparticles; Spryng microparticles perform
in the joint as wet, slippery micro-cushions used in the management
of lameness and other joint related afflictions, such as
osteoarthritis. WVC is the largest veterinary conference that
services the western part of the United States, and normally plays
host to more than 15,000+ participants including many of the top
industry professionals.
“The Western Veterinary Conference provides us
an excellent event to drive forward our innovative veterinary
medical device for the treatment of osteoarthritis, Spryng, with
OsteoCushion Technology” said John Lai, Chief Executive Officer of
PetVivo Holdings, Inc. “We are looking forward to the opportunity
in meeting with veterinarians at the WVC to explain the benefits of
Spryng and how it may be used to enhance the lives of companion
animals.”
For more information about PetVivo Holdings,
Inc. please contact info1@petvivo.com or visit
https://petvivo.com/
Conference Details:
Conference Exhibit Details:
Western Veterinary Conference (WVC)
Booth #: 627
Dates:
Monday, February 20, 2022 9:00am – 5:00pm
Tuesday, February 21, 2022 9:00am – 5:00pm
Wednesday, February 22, 2022 9:00am – 2:00pm
Location: Mandalay Bay Convention Center in Las
Vegas, Nevada
About PetVivo Holdings,
Inc.
PetVivo Holdings Inc. (NASDAQ: PETV & PETVW)
is an emerging biomedical device company currently focused on the
manufacturing, commercialization and licensing of innovative
medical devices and therapeutics for companion animals. The
Company's strategy is to leverage human therapies for the treatment
of companion animals in a capital and time efficient way. A key
component of this strategy is the accelerated timeline to revenues
for veterinary medical devices, which enter the market much earlier
than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for
the treatment of animals and people. A portfolio of nineteen
patents protects the Company's biomaterials, products, production
processes and methods of use. The Company’s lead product SPRYNG™
with OsteoCushion™ technology, a veterinarian-administered,
intraarticular injection for the management of lameness and other
joint related afflictions, including osteoarthritis, in dogs and
horses, is currently available for commercial sale.
For more information about PetVivo Holdings,
Inc. and our revolutionary product, Spryng with OsteoCushion
Technology, please contact info1@petvivo.com or visit
https://petvivo.com/.
CONTACT:
John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
Forward-Looking Statements:
The foregoing material may contain
“forward-looking statements” within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, each as amended. Forward-looking statements
include all statements that do not relate solely to historical or
current facts, including without limitation the Company’s proposed
development and commercial timelines, and can be identified by the
use of words such as “may,” “will,” “expect,” “project,”
“estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,”
“continue” or the negative versions of those words or other
comparable words. Forward-looking statements are not guarantees of
future actions or performance. These forward-looking statements are
based on information currently available to the Company and its
current plans or expectations and are subject to a number of
uncertainties and risks that could significantly affect current
plans. Risks concerning the Company’s business are described in
detail in the Company’s Annual Report on Form 10-K for the year
ended March 31, 2022 and other periodic and current reports filed
with the Securities and Exchange Commission. The Company is under
no obligation to, and expressly disclaims any such obligation to,
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Jun 2024 to Jul 2024
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Jul 2023 to Jul 2024